Cantor Fitzgerald Reiterates Overweight on Reata Pharmaceuticals, Maintains $110 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Reata Pharmaceuticals (NASDAQ:RETA) and maintained a price target of $110.
June 28, 2023 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reata Pharmaceuticals has received an Overweight rating from Cantor Fitzgerald, with a maintained price target of $110.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Reata Pharmaceuticals. The maintained price target of $110 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100